Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells $231,379.50 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi sold 2,274 shares of the company’s stock in a transaction on Monday, May 5th. The shares were sold at an average price of $101.75, for a total value of $231,379.50. Following the transaction, the chief operating officer now directly owns 66,992 shares in the company, valued at $6,816,436. The trade was a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Christina Rossi also recently made the following trade(s):

• On Monday, March 24th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The shares were sold at an average price of $95.02, for a total value of $216,075.48.

Blueprint Medicines Trading Down 0.8 %

Shares of BPMC stock opened at $98.96 on Friday. Blueprint Medicines Co. has a 12 month low of $73.04 and a 12 month high of $121.90. The company has a market cap of $6.39 billion, a PE ratio of -91.63 and a beta of 0.83. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The business’s 50 day moving average is $88.32 and its two-hundred day moving average is $93.67.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.32). The firm had revenue of $149.41 million for the quarter, compared to analyst estimates of $158.31 million. Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. The firm’s revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.40 EPS. Equities analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC bought a new stake in shares of Blueprint Medicines in the fourth quarter valued at approximately $103,356,000. Norges Bank bought a new position in Blueprint Medicines during the fourth quarter worth $62,028,000. Jennison Associates LLC acquired a new position in Blueprint Medicines during the 4th quarter valued at $31,417,000. Rock Springs Capital Management LP boosted its holdings in Blueprint Medicines by 42.7% in the 4th quarter. Rock Springs Capital Management LP now owns 1,096,899 shares of the biotechnology company’s stock valued at $95,672,000 after purchasing an additional 328,123 shares during the period. Finally, Wellington Management Group LLP grew its position in Blueprint Medicines by 8.0% in the 4th quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company’s stock worth $373,421,000 after purchasing an additional 316,754 shares during the last quarter.

Analyst Upgrades and Downgrades

Several analysts recently commented on BPMC shares. Piper Sandler raised their price target on shares of Blueprint Medicines from $109.00 to $119.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. JMP Securities reissued a “market outperform” rating and set a $125.00 target price on shares of Blueprint Medicines in a research note on Friday, February 14th. Jefferies Financial Group assumed coverage on shares of Blueprint Medicines in a research note on Monday, March 17th. They issued a “buy” rating and a $135.00 price target on the stock. Wolfe Research started coverage on Blueprint Medicines in a report on Tuesday, March 18th. They set an “outperform” rating for the company. Finally, Scotiabank started coverage on Blueprint Medicines in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $150.00 target price on the stock. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $126.56.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.